Live-attenuated bacteria as a cancer vaccine vector. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Expert Review of Vaccines Année : 2013

Live-attenuated bacteria as a cancer vaccine vector.

Bertrand Toussaint
  • Fonction : Auteur
  • PersonId : 943543
Xavier Chauchet
  • Fonction : Auteur
Yan Wang
Benoit Polack
  • Fonction : Auteur
Audrey Le Gouellec

Résumé

In the emerging field of active and specific cancer immunotherapy, strategies using live-attenuated bacterial vectors have matured in terms of academic and industrial development. Different bacterial species can be genetically engineered to deliver antigen to APCs with strong adjuvant effects due to their microbial origin. Proteic or DNA-encoding antigen delivery routes and natural bacterial tropisms might differ among species, permitting different applications. After many academic efforts to resolve safety and efficacy issues, some firms have recently engaged clinical trials with live Listeria or Salmonella spp. We describe here the main technological advances that allowed bacteria to become one of the most promising vectors in cancer immunotherapy.

Domaines

Immunité innée
Fichier non déposé

Dates et versions

hal-00918311 , version 1 (13-12-2013)

Identifiants

Citer

Bertrand Toussaint, Xavier Chauchet, Yan Wang, Benoit Polack, Audrey Le Gouellec. Live-attenuated bacteria as a cancer vaccine vector.. Expert Review of Vaccines, 2013, 12 (10), pp.1139-54. ⟨10.1586/14760584.2013.836914⟩. ⟨hal-00918311⟩
1315 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More